- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- February 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- September 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- August 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- August 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- August 2024
- 137 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- February 2025
- 207 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- April 2024
- 30 Pages
Global
From €3090EUR$3,250USD£2,596GBP
- Report
- February 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2025
- 182 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- January 2025
- 209 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- August 2024
- 180 Pages
Asia Pacific
From €3678EUR$3,869USD£3,090GBP
- Report
- January 2025
- 230 Pages
United States
From €2329EUR$2,450USD£1,957GBP
€3327EUR$3,500USD£2,795GBP
- Report
- September 2023
- 170 Pages
Global
From €4562EUR$4,799USD£3,833GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more